Skip to content. | Skip to navigation

National Cancer Institute U.S. National Institutes of Health


Personal tools

You are here: Home / Biomarkers / SELL



This biomarker is also known as:
  • LSEL,
  • PLNHR,
  • LAM1,
  • sL-selectin,
  • LNHR,
  • leukocyte surface antigen Leu-8,
  • Leukocyte adhesion molecule 1,
  • LECAM1,
  • CD62L antigen,
  • CD62L,
  • leukocyte-endothelial cell adhesion molecule 1,
  • LAM-1,
  • gp90-MEL,
  • Leukocyte surface antigen Leu-8,
  • pln homing receptor,
  • lymphocyte adhesion molecule 1,
  • LYAM1,
  • TQ1,
  • Lymph node homing receptor,
  • L-selectin,
  • Leukocyte-endothelial cell adhesion molecule 1,
  • selectin L,
  • hLHRc,
  • CD62 antigen-like family member L,
  • Lyam-1,
  • lymph node homing receptor,
  • LEU8,
  • Leu-8,

View in BioMuta


sL-selectin, also known as SELL, is a cell surface adhesion molecule that belongs to a family of adhesion/homing receptors. SELL mediates the adherence of lymphocytes to endothelial cells of high endothelial venules in peripheral lymph nodes and promotes initial tethering and rolling of leukocytes in endothelia, facilitating their migration into secondary lymphoid organs and inflammation sites. SELL contains a C-type lectin-like domain, a calcium-binding epidermal growth factor-like domain, and two short complement-like repeats. Alternatively spliced transcript variants have been found for this gene.


QA State: Curated
Type: Protein
Short Name:


There are no datasets associated with this biomarker.


The following organs have data associated with this biomarker…



Phase: One
QA State: Under Review


Performance Comment



Phase: Two
QA State: Curated


SELL has not been identified previously in serum as a lung cancer biomarker and represents a novel finding in the aptamer proteomic technology study (Ostroff et al, 2010). A decreased level of SELL was seen in the serum of lung cancer patients compared to controls in this study.

Performance Comment

sL-selectin, also known as SELL, is a member of a 12 protein panel that can discriminate NSCLC from controls with 91% sensitivity and 84% specificity in cross-validated training and 89% sensitivity and 83% specificity in a separate verification set, with similar performance for early and late stage NSCLC.


This biomarker is currently being annotated or is under review. You must be logged in or do not have permission to view any additional information. Contact Heather Kincaid at if you should have access to this biomarker.

2015 Steering Committee Meeting

The next EDRN Steering Committee Meeting will take place March 31st through April 2nd, 2015, in Atlanta, Georgia.

Announcement 12/02/2014

New Round of EDRN FOAs

The RFAs for EDRN have been released:
- Biomarker Developmental Laboratories (U01),
- Clinical Validation Centers (U01),
- Biomarker Reference Laboratories (U24),
- Data Management and Coordinating Center (U24).

EDRN Renewal flyer NOTE-New receipt deadline for applications submitted for all EDRN FOAs is January 20, 2015, by 5:00 PM local time of applicant organization.

There will be a Pre-Application webinar to discuss each of the four individual EDRN FOAs on Tuesday, December 2nd, 2014, from 1pm-5pm (Eastern). Potential applicants interested in participating in the webinar should send a message to Dr. Sharmistha Ghosh ( no later than 5:00 p.m. (EST) November 21, 2014. Please mention the FOA of interest in the subject line.

Announcement 10/07/2014

EDRN Patient Advocates will host an EDRN Advocacy Educational Webinar, Biomarkers for Prostate Cancer Detection and Monitoring, on Monday, January 12th, 2015, at 1 p.m. EDT / 10 a.m. PDT. Registration is not required for this. Please click for more information.